Submissions for variant NM_000116.5(TAFAZZIN):c.461-2A>G

dbSNP: rs876661038

Total submissions: 2

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
GeneDx	RCV000216671	SCV000279309	pathogenic	not provided	2015-05-07	criteria provided, single submitter	clinical testing	Although the c.461-2 A>G mutation has not been reported as a disease-causing mutation or as a benign polymorphism to our knowledge, this mutation destroys the canonical splice acceptor site in intron 5 and is predicted to cause abnormal gene splicing. The mutation is predicted to lead to either an abnormal message that is subject to nonsense-mediated mRNA decay, or to an abnormal protein product if the message is used for protein translation. Other splice site mutations in the TAZ gene have been reported in HGMD in association with Barth syndrome (Stenson P et al., 2014). Furthermore, the c.461-2 A>G mutation was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations.In summary, c.461-2 A>G in the TAZ gene is interpreted as a disease-causing mutation.
Molecular Diagnostics Lab, Nemours Children's Health, Delaware	RCV003236791	SCV003935889	pathogenic	3-Methylglutaconic aciduria type 2	2020-07-22	criteria provided, single submitter	clinical testing